Table 5 Univariate analysis of risk factors associated with growth failure amongst the Chinese patients in this study
Risk Factors | No growth failure (n = 47) | Growth failure (n = 9) | p-value a |
|---|---|---|---|
Patient demographics | |||
 Age at diagnosis | 13 [12–15] | 10 [7.5–12.5] | < 0.01 |
 Male | 8 (17%) | 1 (11.1%) | 1.00 |
 Disease duration (year) | 8.2 [5.5–11.1] | 9.3 [5.85–12.5] | 0.45 |
Laboratory data at diagnosis | |||
 Haemoglobin (g/dL) | 10.6 [9.5–11.9] | 10.55 [9.7–11.5] | 0.73 |
 White cell count (×109/L) | 4 [3.4–6.7] | 6 [3.7–6.9] | 0.14 |
 Platelet (×109/L) | 183 [100.5–265.0] | 198.5 [87.8–261.8] | 0.84 |
 Serum albumin (g/L) | 35 [30.5–40.0] | 37 [32.3–38.8] | 0.87 |
 Serum creatinine (umol/L) | 55 [50.0–68.5] | 52 [43.3–55.5] | 0.28 |
 C3 (g/L) | 0.48 [0.3–0.7] | 0.39 [0.3–0.5] | 0.1 |
 C4 (g/L) | 0.09 [0.05–0.12] | 0.05[0.04–0.08] | 0.25 |
 Anti-dsDNA titre (IU/mL) | 300 [77–300] | 300 [181–300] | 0.34 |
 SLEDAI score at diagnosis | 12 [8–15] | 11 [9–13] | 0.72 |
Disease manifestations over the course of the study period | |||
 Neuropsychiatric manifestations | 5 (10.6%) | 3 (33.3%) | 0.11 |
 Haematological involvement | 32 (68.1%) | 5 (55.6%) | 0.47 |
 Renal involvement | 36 (76.6%) | 8 (88.9%) | 0.67 |
 Serositis | 8 (17%) | 1 (11.1%) | 1.00 |
 Number of major organ involvement | 1 [1–2] | 2 [1–2.5] | 0.64 |
Treatment related factors | |||
 Cumulative dose of CYC (mg/kg) | 27.5 [0–140] | 79 [0–121.5] | 0.79 |
 Ever use of CYC | 26 (55.3%) | 7 (77.8%) | 0.28 |
 Ever use of intravenous MP | 21 (44.7%) | 5 (55.6%) | 0.72 |
Events during course of disease | |||
 Number of lupus flares | 2 [0–6] | 4 [1–6] | 0.33 |
 Episodes of major infection | 1 [0–2] | 1 [0.5–1.5] | 0.37 |